首页 > 市场调查报告书 > 製药

癌症

肿瘤药物市场规模、份额和成长分析（按药物类别、治疗方法、适应症、剂型、通路和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1897903

肿瘤药物市场规模、份额和成长分析（按药物类别、治疗方法、适应症、剂型、通路和地区划分）－2026-2033年产业预测

Oncology Drugs Market Size, Share, and Growth Analysis, By Drug Class (Cytotoxic Drugs, Targeted Drugs), By Therapy (Chemotherapy, Targeted Therapy), By Indication, By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，肿瘤药物市场规模将达到 1,500.8 亿美元，到 2025 年将达到 1,685.4 亿美元，到 2033 年将达到 4,263.2 亿美元，预测期（2026-2033 年）的复合年增长率为 12.3%。

全球癌症治疗市场受到人口老化、生活方式改变和环境因素导致的癌症负担日益加重的显着影响，因此亟需创新的治疗策略。针对各种癌症持续进行研发，并满足尚未满足的医疗需求，对于服务不断增长的患者群体至关重要。分子生物学、基因组学和免疫疗法的进步正在改善癌症治疗，尤其是透过精准医疗，靶向特定的基因突变。然而，这些药物研发高成本，涉及广泛的临床前研究、临床试验和监管核准，可能会限制其应用。儘管存在这些障碍，但精准医疗的整合以及技术创新正为市场成长提供巨大机会，并为肿瘤领域更有效、更安全的药物製剂铺平道路。

肿瘤药物市场驱动因素

全球肿瘤药物市场正经历显着成长，其主要驱动力是全球癌症病例的不断增加。人口老化、生活方式的改变以及环境条件的变化等多种因素导致了癌症发生率的上升。随着癌症患者人数的持续增长，迫切需要开发并广泛应用有效的肿瘤治疗方法。这种日益增长的需求不仅推动了市场发展，也促进了该领域的创新，从而不断改进治疗方案，以期提高患者的治疗效果和存活率。

癌症药物市场的限制

癌症治疗市场发展面临的主要障碍之一是患者获得创新治疗方法的机会有限。医疗保健系统和可用资源的差异，尤其是在发展中和欠发达地区，阻碍了最先进治疗的广泛应用。此外，保险覆盖范围和报销政策的差异进一步限制了患者的治疗机会，最终影响这些重要治疗方法的可及性。应对这些挑战对于改善肿瘤治疗至关重要，因为缺乏新型疗法会阻碍整体市场成长和患者疗效。

肿瘤药物市场趋势

在基因谱分析和生物标记识别技术的进步推动下，癌症药物市场正经历着向个人化医疗的重大转变。这一趋势促进了针对个别患者需求量身定制治疗方案的开发，从而在提高疗效的同时最大限度地减少併发症。随着医疗机构和製药公司积极采用这些标靶治疗，患者的治疗效果正在改善，传统的「一刀切」治疗方法正逐渐被取代。这种对个人化癌症治疗的关注不仅推动了药物研发的创新，也激发了投资者的兴趣和需求，最终将改变癌症治疗格局，并以更先进的方式改善患者照护。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲（MEA）
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争格局

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市集活动
主要企业市占率（2025 年）

主要企业简介

F. Hoffmann-La Roche Ltd.（Switzerland）
Amgen（US）
Novartis AG（Switzerland）
Bristol-Myers Squibb Company（US）
Pfizer Inc.（US）
Astellas Pharma Inc.（Japan）
Johnson & Johnson（US）
AstraZeneca plc（UK）
AbbVie Inc.（US）
Merck & Co., Inc.（US）
Eli Lilly and Company（US）
Sanofi SA（France）
Gilead Sciences, Inc.（US）
Regeneron Pharmaceuticals, Inc.（US）
Incyte Corporation（US）
Vertex Pharmaceuticals Incorporated（US）
Seagen Inc.（US）
Blueprint Medicines Corporation（US）
Mirati Therapeutics, Inc.（US）
Xencor, Inc.（US）
NantKwest, Inc.（US）
Zymeworks Inc.（Canada）
Karyopharm Therapeutics Inc.（US）
Exelixis, Inc.（US）

简介目录

Product Code: SQMIG35J2087

Oncology Drugs Market size was valued at USD 150.08 Billion in 2024 and is poised to grow from USD 168.54 Billion in 2025 to USD 426.32 Billion by 2033, growing at a CAGR of 12.3% during the forecast period (2026-2033).

The global oncology drugs market is significantly influenced by the rising cancer burden driven by an aging population, evolving lifestyles, and environmental factors, necessitating innovative treatment strategies. Continuous research and development in various cancers, alongside unmet medical needs, are crucial to catering to a growing patient base. Advances in molecular biology, genomics, and immunotherapy are enhancing cancer therapeutics, particularly through precision medicine that targets specific genetic mutations. However, the high costs of developing these drugs, due to extensive preclinical research, clinical trials, and regulatory approvals, may limit their accessibility. Despite these hurdles, the integration of precision medicine, fueled by technological innovations, presents substantial opportunities for market growth, paving the way for more effective and safer drug formulations in oncology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Oncology Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Oncology Drugs Market Segments Analysis

Global Oncology Drugs Market is segmented by Drug Class, Therapy, Indication, end user and region. Based on Drug Class, the market is segmented into Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others. Based on Therapy, the market is segmented into Chemotherapy, Targeted Therapy, andImmunotherapy. Based on Indication, the market is segmented into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, and Others. Based on Dosage Form, the market is segmented into automotive, consumer electronics, healthcare, agriculture, manufacturing, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Oncology Drugs Market

The global oncology drugs market is experiencing significant growth primarily driven by the rising prevalence of cancer cases across the globe. Several factors contribute to this escalating incidence, including an aging population, evolving lifestyle choices, and shifts in environmental conditions. As the number of individuals affected by cancer continues to rise, there is an urgent demand for the development and accessibility of effective oncology treatments. This growing need not only propels the market forward but also fosters innovation within the field, leading to the continuous advancement of therapeutic options aimed at improving patient outcomes and survival rates.

Restraints in the Oncology Drugs Market

One significant barrier to the advancement of the oncology drugs market is the restricted access to innovative therapies for patients. Disparities in healthcare systems and available resources, particularly in developing and underdeveloped regions, can impede the distribution of state-of-the-art treatment options. Additionally, variations in insurance coverage and reimbursement practices further limit patient access, ultimately impacting the uptake of these crucial therapies. This lack of accessibility to novel treatments can hinder overall market growth and patient outcomes, making it essential to address these challenges for the betterment of oncology care.

Market Trends of the Oncology Drugs Market

The oncology drugs market is witnessing a significant shift towards personalized medicine, driven by advancements in genetic profiling and biomarker identification. This trend is fostering the development of customized therapies tailored to individual patient needs, enhancing treatment efficacy while minimizing complications. As healthcare providers and pharmaceutical companies increasingly adopt these targeted approaches, patients are experiencing improved outcomes, displacing traditional one-size-fits-all treatments. This focus on personalized oncology not only fuels innovation in drug development but also boosts investor interest and demand, ultimately transforming the landscape of cancer treatment and improving patient care in a more sophisticated manner.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Oncology Drugs Market by Drug Class

Market Overview
Cytotoxic Drugs
- Alkylating Agents
- Antimetabolites
- Others
Targeted Drugs
- Monoclonal Antibodies
- Others
Hormonal Drugs
Others

Oncology Drugs Market by Therapy

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy

Oncology Drugs Market by Indication

Market Overview
Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Others

Oncology Drugs Market by Dosage Form

Market Overview
Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled Syringes
- Others

Oncology Drugs Market by Distribution Channel

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Oncology Drugs Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Incorporated (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seagen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Blueprint Medicines Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mirati Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xencor, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Karyopharm Therapeutics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments